Reduction of pharmaceutical expenditure by a drug appropriateness intervention in polymedicated elderly subjects in Catalonia (Spain) / Lluís Campins [i 5 més]Material type: ArticleContent type: text Media type: informàtic Carrier type: recurs en líniaSubject(s): Receptes mèdiques | Despesa farmacèutica | Estudis de casos i controlOnline resources: Accés lliure
|Item type||Current location||Collection||Call number||url||Status||Notes||Date due||Barcode|
|Journal article||Escola Universitària d'Infermeria i Teràpia Ocupacional de Terrassa Internet||En línia||Link to resource||Exclòs de préstec||0001017285930|
|Journal||Escola Universitària d'Infermeria i Teràpia Ocupacional de Terrassa Internet||En línia||Link to resource||Exclòs de préstec||Consulta en línia: 1987(vol. 1 n. 1) -- + suplements||285412|
Mateu Serra-Prat, Elisabet Palomera, Ignasi Bolibar, Miquel Àngel Martínez, Pedro Gallo
To assess the monetary savings resulting from a pharmacist intervention on the appropriateness of prescribed drugs in community-dwelling polymedicated (≥8 drugs) elderly people (≥70 years).
An evaluation of pharmaceutical expenditure reduction was performed within a randomised, multicentre clinical trial. The study intervention consisted of a pharmacist evaluation of all drugs prescribed to each patient using the “Good Palliative-Geriatric Practice” algorithm and the “Screening Tool of Older Persons Prescriptions/Screening Tool to Alert doctors to Right Treatment” criteria (STOPP/START). The control group followed the routine standard of care. A time horizon of one year was considered and cost elements included human resources and drug expenditure.
490 patients (245 in each group) were analysed. Both groups experienced a decrease in drug expenditure 12 months after the study started, but this decrease was significantly higher in the intervention group than in the control group (−14.3% vs.−7.7%; p=0.041). Total annual drug expenditure decreased 233.75 €/patient (95% confidence interval [95%CI]: 169.83-297.67) in the intervention group and 169.40 €/patient (95%CI: 103.37-235.43) in the control group over a one-year period, indicating that 64.30 € would be the drug expenditure savings per patient a year attributable to the study intervention. The estimated return per Euro invested in the programme would be 2.38 € per patient a year on average.
The study intervention is a cost-effective alternative to standard care that could generate a positive return of investment.